Sidd
Sidd

Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
WASHINGTON, May 7, 2012 /PRNewswire-USNewswire/ -- A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

IGY Immune Technology & Life Sciences Purchases Manufacturing Facility to Produce Purified Immunoglobulin Y (IgY)
T

Seahorse Announces the XF Glycolysis Stress Test Kit
BILLERICA, Mass., April 25, 2012 /PRNewswire/ -- Seahorse Bioscience, the leader in cellular bioenergetic measurements, announced the launch of its newest stress test kit at the American Association of Cancer Research (AACR) Annual Meeting 2012.


Related News:


Privacy Policy | Copyright/Trademark Notification